Evolving strategies in the treatment of sepsis and systemic inflammatory response syndrome (SIRS)

被引:54
作者
Horn, KD [1 ]
机构
[1] Univ Pittsburgh, Med Ctr, Dept Pathol, Pittsburgh, PA 15213 USA
来源
QJM-MONTHLY JOURNAL OF THE ASSOCIATION OF PHYSICIANS | 1998年 / 91卷 / 04期
关键词
D O I
10.1093/qjmed/91.4.265
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
In recent years, much basic science research has investigated the predisposing factors, initiation, propagation, and resolution of Cram-negative sepsis, endotoxaemic shock, and the newly defined entity of systemic inflammatory response syndrome (SIRS). A major cause of morbidity and mortality in the post-surgical, neonatal, and geriatric hospital population, sepsis has proven itself notoriously resistant to classical modes of therapy, including antibiotics, fluid/pressor and respiratory support. Recently, the widespread nosocomial isolation of new antibiotic-resistant strains of endotoxin-producing bacteria has further complicated management. For these reasons, there is much interest in alternative treatment modalities which focus upon the endotoxin molecule itself and the systemic inflammatory response it provokes via the cytokine, complement, and coagulation cascades. In this review, recent experimental approaches to the therapy of sepsis and SIRS are discussed in light of each step in the complex inflammatory cascade and in comparison to traditional approaches to prevention and therapy of Gram-negative bacteraemia and septic shock.
引用
收藏
页码:265 / 277
页数:13
相关论文
共 130 条
[1]  
Abrahamson SL, 1997, J BIOL CHEM, V272, P2149
[2]   HEMODYNAMIC-RESPONSES TO GRAM-POSITIVE VERSUS GRAM-NEGATIVE SEPSIS IN CRITICALLY ILL PATIENTS WITH AND WITHOUT CIRCULATORY SHOCK [J].
AHMED, AJ ;
KRUSE, JA ;
HAUPT, MT ;
CHANDRASEKAR, PH ;
CARLSON, RW .
CRITICAL CARE MEDICINE, 1991, 19 (12) :1520-1525
[3]   LIMITATION OF REPERFUSION INJURY BY A MONOCLONAL-ANTIBODY TO C5A DURING MYOCARDIAL-INFARCTION IN PIGS [J].
AMSTERDAM, EA ;
STAHL, GL ;
PAN, HL ;
RENDIG, SV ;
FLETCHER, MP ;
LONGHURST, JC .
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY, 1995, 268 (01) :H448-H457
[4]   TREATMENT OF SEPSIS BY EXTRACORPOREAL ELIMINATION OF ENDOTOXIN USING POLYMYXIN B-IMMOBILIZED FIBER [J].
AOKI, H ;
KODAMA, M ;
TANI, T ;
HANASAWA, K .
AMERICAN JOURNAL OF SURGERY, 1994, 167 (04) :412-417
[5]   PRETREATMENT OF NORMAL HUMANS WITH MONOPHOSPHORYL LIPID-A INDUCES TOLERANCE TO ENDOTOXIN - A PROSPECTIVE, DOUBLE-BLIND, RANDOMIZED, CONTROLLED TRIAL [J].
ASTIZ, ME ;
RACKOW, EC ;
STILL, JG ;
HOWELL, ST ;
CATO, A ;
VONESCHEN, KB ;
ULRICH, JT ;
RUDBACH, JA ;
MCMAHON, G ;
VARGAS, R ;
STERN, W .
CRITICAL CARE MEDICINE, 1995, 23 (01) :9-17
[6]   Comparison of the efficacy of pentoxifylline and albifyllin (HWA 138) on endotoxin-induced cytokine production, coagulation disturbances, and mortality [J].
Bahrami, S ;
Yao, YM ;
Shiga, H ;
Leichtfried, G ;
Redl, H ;
Schlag, G .
SHOCK, 1996, 5 (06) :424-428
[7]  
Baker CC, 1995, CURR PROB SURG, V32, P1018
[8]  
BERNARD GR, 1997, NEW ENGL J MED, V336, P952
[9]  
BERNARD GR, 1994, UPD INT CAR, V18, P464
[10]  
BEUTLER BA, 1989, MOL CELLULAR MECHANI, P219